Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. Range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range

Journal of Urology

Volumn 168, Issue 2, 2002, Pages 504-508

  Haese, Alexander ^a,b   Dworschack, Robert T ^a,b   Partin, Alan W ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Immunoassay; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CLINICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

EID: 0036071723     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64668-X     Document Type: Article

References (14)

1. The value of screening tests in the detection of prostate cancer. Part 1: Results of a retrospective evaluation of 726 men
2. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium
3. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6630 men
4. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
5. Prostate cancer detection in men with serum PSA concentrations of 2.6-4 ng./ml. and benign prostate examination. Enhancement of specificity with free PSA measurements
6. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men
7. Prostate cancer detection at low prostate-specific antigen
8. Prospective detection of clinically relevant prostate cancer in the prostate-specific antigen range 1-3 ng./ml. combined with free-to-total ratio 20% or less: The Aarau experience
9. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. prostatespecific antigen
10. Prostate cancer screening within a prostate-specific antigen range of 3 to 3.9 ng./ml.: A comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests
11. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA-levels are 2.51-4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model
12. Serial prostatic biopsies in men with persistently elevated serum prostate-specific antigen values
13. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
14. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease